CASR and neoplasm: Although U937CD33 and Nalm6CD33 cells grew at different rates in mice, we observed a faster disease progression and shorter survival in mice bearing U937CD33 cells at different initial CAR T-to-tumor cell ratios (Supplementary Fig. 1E).